Efficacy and safety of tranexamic acid in reducing blood loss in lower segment caesarean section: a prospective, randomised, double-blind and case-controlled study

Suganya Bhuvaneshwaran; Veena Vasudevan Christy; Aro Shime Hercules; K. Soundarya

doi:10.18203/2320-1770.ijrcog20261608

Authors

Suganya Bhuvaneshwaran Department of Obstetrics and Gynecology, Melmaruvathur Athiparasakthi Medical College, Melmaruvathur, Tamil Nadu, India
Veena Vasudevan Christy Sree Balaji Medical College and Hospital, Chennai, Tamil Nadu, India
Aro Shime Hercules Melmaruvathur Athiparasakthi Medical College, Melmaruvathur, Tamil Nadu, India
K. Soundarya Anbu Multispeciality Hospital, Kumbakonam, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20261608

Keywords:

Antifibrinolytic, Blood loss, Caesarean section, Postpartum hemorrhage, Randomized controlled trial, Tranexamic acid

Abstract

Background: Cesarean section (CS) rates are rising globally, and postpartum haemorrhage remains a major cause of maternal morbidity. Tranexamic acid (TXA), an antifibrinolytic agent, has been shown to reduce bleeding in various surgical settings, but its routine prophylactic use in CS requires further evaluation. This study aimed to assess the efficacy and safety of preoperative intravenous tranexamic acid in reducing blood loss during lower segment cesarean sections (LSCS).

Methods: This prospective, randomized, double-blind, placebo-controlled study was conducted at a tertiary care hospital in Chennai, India, from December 2015 to November 2016. A total of 100 term women undergoing LSCS under spinal anaesthesia were randomly assigned to receive either 1 gm TXA (n=50) or placebo (30 ml 5% dextrose, n=50) intravenously 20 minutes before skin incision. Both groups received 10 IU oxytocin after delivery. The primary outcome was estimated blood loss (EBL) calculated from changes in haematocrit. Secondary outcomes included postoperative hemoglobin (Hb), packed cell volume (PCV), the need for additional uterotonics, maternal side effects, neonatal APGAR scores, and thromboembolic events up to 6 weeks postpartum.

Results: The mean EBL was significantly lower in the TXA group compared to the placebo group (332. 62±172. 66 ml versus 413. 38±252. 21 ml; p=0.043). Postoperative Hb and PCV were preserved in the TXA group (with declines of 0.01 gm/dl and 0. 04%, respectively), whereas significant decreases occurred in the placebo group (declines of 1.00 gm/dl and 2.10%; p<0.0001). No patient in the TXA group experienced EBL>1000 ml versus two (4%) in the placebo group. Additional uterotonics were needed in 6% (TXA) and 12% (placebo) (p=0.294). Maternal side effects were mild and similar between groups (8% each). No thromboembolic events were observed in either group. Neonatal APGAR scores and NICU admission rates were comparable.

Conclusions: Preoperative intravenous tranexamic acid significantly reduces blood loss during and after caesarean section, with an excellent safety profile for both mother and neonate. Prophylactic TXA should be considered as a routine intervention in LSCS, particularly in settings where blood transfusion resources are limited.

References

Yehia AH, Koleib MH, Abdelazim IA, Ahmed A. Tranexamic acid reduces blood loss during and after cesarean section: a double blinded, randomized, controlled trial. Asian Pac J Reprod. 2014;3(1):53-6.

Sentürk MB, Cakmak Y, Yildiz G, Yildiz P. Tranexamic acid for cesarean section: a double-blind, placebo-controlled, randomized clinical trial. Arch Gynecol Obstet. 2013;287(4):641-5.

Shakur H, Elbourne D, Gülmezoglu M, Alfirevic Z, Ronsmans C, Allen E, et al. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials. 2010;11:40.

Soltani S, Mirteimouri M, Movahedian A, Chalakinia N. Preventive and therapeutic effects of tranexamic acid on postpartum bleeding. Rev Clin Med. 2015;2(1):37-41.

Kandappan G, Anand B. Efficacy of tranexamic acid in decreasing blood loss during and after cesarean section in multigravida parturients: a case controlled prospective study. J Evid Based Med Healthcare. 2016;3(48),2419-25.

Davis S. Tranexamic acid for postpartum hemorrhage. Glob J Med Res Gynecol Obstet. 2014;14(1).

Ramani B, Nayak L. (2017). Intravenous 1 gram tranexamic acid for prevention of blood loss and blood transfusion during cesarean section: a randomized case control study. Int J Reprod Contracept Obstet Gynecol. 2017;3(2):366-9.

Goswami U, Sarangi S, Gupta S, Babbar S. Comparative evaluation of two doses of tranexamic acid used prophylactically in anemic parturients for lower segment cesarean section: a double-blind randomized case control prospective trial. Saudi J Anaesth. 2013;7(4):427-31.

Kratzer S, Irl H, Mattusch C, Bürge M, Kurz J, Kochs E, et al. Tranexamic acid impairs γ-aminobutyric acid receptor type A-mediated synaptic transmission in the murine amygdala: a potential mechanism for drug-induced seizures? Anesthesiology. 2014;120(3):639-49.

CRASH-2 trial collaborators; Shakur H, Roberts I, Bautista R, Caballero J, Coats T, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32.

Viswanath O, Santhosh S, Goldman H. The evolving role of prophylactic use of tranexamic acid before cesarean section: balance between maternal benefits and unknown neonatal effects. J Anesthesiol Clin Sci. 2015;4:4.

Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000;(4):CD000249.

Xu J, Gao W, Ju Y. Tranexamic acid for the prevention of postpartum hemorrhage after cesarean section: a double-blind randomization trial. Arch Gynecol Obstet. 2013;287(3):463-8.

Gungorduk K, Yıldırım G, Asıcıoğlu O, Gungorduk OC, Sudolmus S, Ark C. Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study. Am J Perinatol. 2011;28(3):233-40.

Movafegh A, Eslamian L, Dorabadi A. Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery. Int J Gynecol Obstet. 2011;115(3):224-6.

Bellos I, Pergialiotis V. Tranexamic acid for the prevention of postpartum hemorrhage in women undergoing cesarean delivery: an updated meta-analysis. Am J Obstet Gynecol. 2022;226(4):510-23.e22.

WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105-16. Erratum in: Lancet. 2017;389(10084):2104.

Alam A, Choi S. Prophylactic use of tranexamic acid for postpartum bleeding outcomes: a systematic review and meta-analysis of randomized controlled trials. Transfus Med Rev. 2015;29(4):231-41.

Rohwer C, Rohwer A, Cluver C, Ker K, Hofmeyr GJ. Tranexamic acid for preventing postpartum haemorrhage after cesarean section. Cochrane Database Syst Rev. 2024;11(11):CD016278.

Wang HY, Hong SK, Duan Y, Yin HM. Tranexamic acid and blood loss during and after cesarean section: a meta-analysis. J Perinatol. 2015;35(10):818-25.

Novikova N, Hofmeyr GJ. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2015;(6):CD007872.